HUTCHMED (China) (HCM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
792.7mn → 872.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
−21.1% YoY in FY25 · 2.6% of revenue.
$0.0M returned vs $−78.8M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
83¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Over this window: gross 27.5% → 38.7%. Net margin 83.4% is more than double the sector median.
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 548,512.0 | 548,512.0 | 630,201.0 | 837,999.0 | 426,409.0 | 356,128.0 | ▼13.0% | +11.4% |
Cost of revenue | 336,349.0 | 336,349.0 | 348,884.0 | 384,447.0 | 311,103.0 | 258,234.0 | ▼3.6% | +6.8% |
Gross profit | 212,163.0 | 212,163.0 | 281,317.0 | 453,552.0 | 115,306.0 | 97,894.0 | ▼24.6% | +21.3% |
Research & development | 148,295.0 | 148,295.0 | 212,109.0 | 302,001.0 | 386,893.0 | 299,086.0 | ▼30.1% | −16.1% |
Selling, general & admin | 103,028.0 | 103,028.0 | 112,913.0 | 133,176.0 | 136,106.0 | 127,125.0 | ▼8.8% | −5.1% |
Total operating expenses | 251,323.0 | 251,323.0 | 325,022.0 | 435,177.0 | 522,999.0 | 426,211.0 | ▼22.7% | −12.4% |
Operating incomefeeds ROC rank | −39,160.0 | −39,160.0 | −43,705.0 | 18,375.0 | −407,693.0 | −328,317.0 | ▲10.4% | — |
Other income, net | 537,851.0 | 537,851.0 | 42,598.0 | 39,933.0 | −2,729.0 | 112,577.0 | — | — |
Pretax income | 498,691.0 | 498,691.0 | −1,107.0 | 58,308.0 | −410,422.0 | −215,740.0 | — | — |
Income tax | 63,610.0 | 63,610.0 | 7,192.0 | 4,509.0 | −283.0 | 11,918.0 | ▲784.5% | +52.0% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 457,732.0 | 457,732.0 | 38,170.0 | 101,094.0 | −360,386.0 | −167,041.0 | ▲1099.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.52 | 0.52 | 0.04 | 0.12 | −0.43 | −0.25 | ▲1200.0% | — |
Diluted shares (mn) | 872.89 | 872.89 | 872.83 | 869.20 | 847.14 | 792.68 | ▲0.0% | +2.4% |
| Margins | ||||||||
Gross margin19th pct in Healthcare | 38.7% | 38.7% | 44.6% | 54.1% | 27.0% | 27.5% | ▼6.0pp | +11.2pp |
Operating margin | −7.1% | −7.1% | −6.9% | 2.2% | −95.6% | −92.2% | ▼0.2pp | +85.1pp |
Net margin | 83.4% | 83.4% | 6.1% | 12.1% | −84.5% | −46.9% | ▲77.4pp | +130.4pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was HUTCHMED (China)'s revenue last fiscal year?
HUTCHMED (China) reported revenue of $548.5M in fiscal 2025, down 13.0% from fiscal 2024.
What was HUTCHMED (China)'s net income?
HUTCHMED (China) reported net income of $457.7M in fiscal 2025, a net margin of 83.4%.

